SCHEMBL2964292

SCHEMBL2964292

CCOC(=O)COc1nc2nc(N3CCN(C(=O)OC(C)(C)C)CC3)n(-c3ccccc3Cl)c2c(=O)n1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.44
CNR2 P34972 2/20 0.44
MAPT P10636 3/20 0.42
TSHR P16473 2/20 0.42
HSD17B10 Q99714 1/20 0.42
GAA P10253 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
SLC6A4 P31645 1/20 0.38
CKS1B P61024 2/20 0.38
SKP1 P63208 2/20 0.38
SKP2 Q13309 2/20 0.38
CCNK O75909 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CCND3 P30281 1/20 0.37
CDK9 P50750 1/20 0.37
CDK6 Q00534 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2957100 0.84 CNR1 (0.43) CNR1CNR2MAPTTSHRHSD17B10
SCHEMBL2954897 0.78 GAA (0.44) CNR1CNR2MAPTTSHRHSD17B10
SCHEMBL5719246 0.77 L3MBTL1 (0.45) CNR1CNR2MAPTTSHRGAA
SCHEMBL13200001 0.77 DPP4 (0.44) HSD17B10L3MBTL1HTR2AHTR2CSMN1; SMN2
SCHEMBL2954278 0.76 DPP4 (0.40) MAPTTSHRHSD17B10L3MBTL1HTR2A
SCHEMBL2956192 0.76 CNR1 (0.45) CNR1CNR2MAPTTSHRHSD17B10
SCHEMBL5718793 0.75 MEN1 (0.42) CNR1CNR2MAPTTSHRGAA
SCHEMBL5719021 0.74 L3MBTL1 (0.42) CNR1CNR2MAPTTSHRGAA
SCHEMBL2952792 0.74 L3MBTL1 (0.42) CNR1CNR2MAPTTSHRHSD17B10
SCHEMBL5719186 0.74 L3MBTL1 (0.44) CNR1CNR2MAPTTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772226-B2 Condensed imidazole derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-10 US disclosed
US-20090018331-A1 CONDENSED IMIDAZOLE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-01-15 US disclosed
US-20070219178-A1 PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS EISAI CO., LTD. (JP) 2007-09-20 US disclosed
US-20060100199-A1 Novel condensed imidazole derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-05-11 US disclosed
US-20060094722-A1 Combination drug EISAI CO., LTD. (JP) 2006-05-04 US disclosed
US-20060063787-A1 Condensed imidazole derivatives EISAI CO., LTD. (JP) 2006-03-23 US disclosed
EP-1557165-A1 COMBINATION DRUG Eisai Co., Ltd. (JP) 2005-07-27 EP disclosed
EP-1514552-A1 NOVEL FUSED IMIDAZOLE DERIVATIVE Eisai Co., Ltd. (JP) 2005-03-16 EP disclosed
US-20040116328-A1 Condensed imidazole derivatives EISAI CO., LTD. (JP) 2004-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219178-A1 PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS MYT1, AQP4, AQP1 CNR1 100/4885CNR2 294/4885MAPT 1188/4885
US-20060100199-A1 Novel condensed imidazole derivatives H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4 CNR1 296/4885CNR2 254/4885MAPT 2594/4885
US-20060094722-A1 Combination drug DPP4, GLP1R, DPP7 CNR1 3506/4885CNR2 2971/4885MAPT 4004/4885
US-20060063787-A1 Condensed imidazole derivatives DPP4, HDAC1, DPP7 CNR1 1118/4885CNR2 1499/4885MAPT 4084/4885
US-20090018331-A1 CONDENSED IMIDAZOLE DERIVATIVES DPP4, HDAC1, DPP7 CNR1 1118/4885CNR2 1499/4885MAPT 4084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.